THE 30STARTUPS OF KANSAI

Cuorips is an academia-spun biotech company leading the global commercialization of iPS cell-based regenerative medicine. Driven by our mission — a world where no one dies of heart disease — we are building breakthrough treatments for conditions once thought incurable. Our proprietary cell-culturing facility CLiC-1 powers next-generation cell therapies and CDMO services for partners worldwide. With a strong technology foundation and manufacturing scale, Cuorips is positioned to make Japan-originated regenerative medicine a new global standard of cardiac care.

Severe heart failure is a multi-billion-dollar global health crisis, with treatment options long limited to scarce, highly invasive heart transplants. Cuorips is changing that. Our iPS cell-derived cardiomyocyte sheets, RiHeart®, are transplanted directly onto damaged heart tissue, releasing cytokines that trigger genuine functional recovery. By offering a proven, scalable alternative to organ transplantation, we remove donor dependency, reduce the burden on healthcare systems, and give patients around the world a real path back to health.

Our uniqueness is proven: RiHeart® is the world’s first approved iPS cell-derived cardiac therapy, built on three proprietary technologies.

Safety: An advanced purification process removes undifferentiated cells, minimizing tumorigenesis risk. Speed and Precision: Our sheet-transplantation method cuts surgery time to just 50 minutes while lowering arrhythmia risk.
Reach: A specialized logistics solution enables two-day, room-temperature transport, so therapies arrive ready for immediate implantation anywhere in the world.

Combined with CLiC-1, our commercial-scale manufacturing facility, these technologies give Cuorips a competitive edge.

Building on this proven technology, Cuorips is accelerating its global expansion toward a world where no one dies of heart disease. Three pillars will drive our next phase of growth.

Catheter Delivery: A minimally invasive procedure that will expand patient eligibility and lower procedural burden. YS Series: Novel small-molecule therapeutics that promote systemic tissue regeneration for a variety of organs.
CDMO Services: Leveraging CLiC-1 to deliver end-to-end manufacturing solutions for partners worldwide.

Backed by VMaCS, our scalable mass-production platform, Cuorips is set to lead the next era of regenerative medicine — from Japan to the world.